Thechristieclinic.co.uk
Haemato-oncology and stem cell
transplant unit for private patients
Welcome to The Christie Clinic
The Christie Clinic is a joint partnership between
made in both treatment and supportive care leading
the world famous Christie NHS Foundation Trust
to improved survival. It is vital patients are diagnosed
and leading healthcare provider HCA International.
early, seen by the right specialist and offered the
Together they have created one of the world's most
most effective treatment programme.
advanced cancer clinics for private patients.
At The Christie Clinic we offer the highest standards
Approximately 28,500 people are diagnosed with
of care and most up to date treatments, delivered
haematological cancers (leukaemia, lymphoma and
by leading experts in a clean and comfortable
myeloma) each year in the UK. For many of these
diseases there has been considerable progress
ContentsA world class facility for haematological cancers
Our consultant team - leaders in the field
Our haematology nursing team
Our haematology unit
Our leukaemia and myeloma service
Our lymphoma service
Our stem cell transplant service
Our diagnostic and laboratory service
Supportive and complementary care
Making a referral
Photography by David Oates
A world class facility
for treatment of
haematological cancersA new purpose built haematology and transplant unit has been established at The Christie Clinic and provides the only dedicated private bone marrow (stem cell) transplant facility in the UK outside London. We offer treatment for the full range of malignant haematological disorders and provide a fully comprehensive service including bone marrow (stem cell) transplantation to patients over 16 years old.
The inpatient facility utilises state of the art infection control technologies and adheres to the strictest standards of cleanliness and hygiene. All rooms are HEPA (high efficiency particulate air) filtered and specifically designed to accommodate the needs of patients undergoing intensive chemotherapy.
World class haematologists and oncologists choose to treat their patients at The Christie Clinic. These consultants are supported by a highly accomplished multidisciplinary team of clinical nurse specialists, transplant co-ordinators and nurse clinicians. These specialists make up a team dedicated to our patients' needs. They are available to treat, advise and guide patients throughout their diagnosis and treatment programme, and to ensure patients are in a position to make informed decisions about their care.
"Having my treatment
here has changed my life."Caroline Whitfield
Our consultant team –
leaders in the field Our consultant team has a strong national and international profile in the management of haematological malignancies and leads an active research programme.
The haematology and transplant unit is delivering a wide portfolio of clinical trials covering the range of haematological malignancies.
Dr Adrian Bloor
Consultant Haematologist
MA MB BChir PhD FRCP FRCPath
Dr Adrian Bloor is Lead Clinician in lymphoid malignancies at The Christie hospital, Director of The Christie Stem Cell Transplant Programme and Clinical Director of The Christie Clinical Trials Co-ordination Unit. He is a member of the National Cancer Research Network (NCRN) chronic lymphocytic leukaemia (CLL) trials group, secretary to the executive committee of the UK CLL Forum and a member of the medical advisory panel to the Lymphoma Association. Dr Bloor is a member of the clinical trials committee of the British Society of Bone Marrow Transplantation (BSBMT) and European Group for Blood and Marrow Transplantation.
Dr Mike Dennis
Consultant Haematologist
MB ChB MD MRCP FRCPath
Dr Mike Dennis was appointed as Consultant Haematologist at The Christie in 2004, and is Clinical Director of the haematology and transplant unit. He is a member of the British Society for Haematology, the Royal College of Physicians, the Royal College of Pathologists and the European Group for Blood and Marrow Transplantation (EBMT). Dr Dennis is also a national committee member of the acute myeloid leukaemia (AML) NCRN working group, which is responsible for the development of clinical trials and governance for international multicentre trials in AML. In addition, he is a national committee member of the NCRN myelodysplasia (MDS) forum and clinical trials subgroup, responsible for UK clinical trial development.
Professor Tim Illidge
Consultant Clinical Oncologist
BSc MB BS PhD DRCOG MRCP FRCR FRCPath
Professor Tim Illidge is a member of the NCRN lymphoma clinical studies group and a member of the medical advisory panel to the Lymphoma Association. He is a member of the International Working Group on Non- Hodgkin Lymphoma and has represented the UK on numerous international steering groups, having published and lectured extensively in the field of lymphoma.
Dr Samar Kulkarni
Consultant Haematologist
MB BS MD MRCP FRCPath
Dr Samar Kulkarni has worked at The Christie since 2010 and has worked in the field of haemato-oncology and transplantation since 1992. He is a member of the American Society of Hematology, American Society of Bone Marrow Transplantation and European Group for Blood and Marrow Transplantation. Dr Kulkarni has published extensively in the field of leukaemia, myeloma and transplantation. His other areas of interest include treatment of young adult patients with haematological disorders.
Dr Ed Smith
Consultant Clinical Onocologist
MA BM BCh MRCP FRCR
Dr Ed Smith treats lymphoma and other haematological malignancies with chemotherapy and radiotherapy. He has special interest in treating younger patients as well as research interests in advanced radiotherapy, patient support, monitoring and information giving in relation to the late effects of cancer treatment. Dr Smith is also The Christie survivorship lead for young people and a member of the Children's Cancer and Leukaemia Group (CCLG) bone marrow transplant committee as well as a member of the Royal College of Radiologists (RCR) specialist training committee.
Our haematology nursing team
Our nursing team has many years of experience in haematology and stem cell transplantation. They are highly skilled in caring for patients undergoing intensive chemotherapy and are committed to providing the highest standards of treatment and support to their patients in a caring and friendly manner.
Specialist nursing staff
The haematology unit is supported by a team of specialist
nursing staff.
Isobel Kearney leads the ward nursing team
and is the senior sister on the unit. She has an
outstanding record of ensuring that staff are
trained and work to the highest standards to
provide a friendly and caring environment
for both staff and patients.
Ann Davis is a nurse clinician who assists
in the care of our patients both on the ward
and in the clinic. In addition to her extensive
experience in haematology nursing, she
has undertaken further training as an
advanced practitioner.
Ruth Clout was appointed as Clinical Practice
Educator in 2011 to develop the educational
and training programme for the nursing
staff, ensuring that we achieve the highest
standards of care.
Our haematology unit
The haematology unit at The Christie Clinic is centred upon patients' needs. We know that whilst some stays may be short others, particularly for our transplant patients, are likely to be longer. For this reason, every room is spacious and equipped to the highest standard.
Stem cell collection facility
Stem cell collection is undertaken in a purpose built daycase facility
run by a dedicated team of experienced nurses utilising the latest
technology (CaridianBCT Optia).
Inpatient facility
Infection control is of the highest priority and each room is HEPA filtered
to ensure the cleanest air and optimal recovery. All staff follow strict
infection control policies to create a clean and safe environment
for our patients.
Each room has a personal entertainment system which is built into the wall to maintain infection control standards. This can be operated from the patient's bed and has a wide range of digital and satellite TVchannels, movies, radio and wi-fi internet access.
Support during their stay
Through our partnership with The Christie NHS Foundation Trust,
our patients have direct access to advanced intensive and critical care
units and sophisticated operating theatres, as well as the extensive
infrastructure one would expect from such a large and innovative
NHS hospital. This provides our patients and their families with the
reassurance that should these facilities be required they are all
available on one site.
Research and training
Our team of highly skilled consultants, medical and nursing staff
is actively engaged in research and are able to provide a wide range
of clinical trials as well as offer the latest and most advanced haemato-
"The haematology unit at The Christie
oncology treatment. These consultants are supported by a team of highly experienced nurses who all specialise in the haematology field.
Clinic offers world class treatment
We are continually investing in the training of our nursing team to
for patients with haematological
enhance their expertise as new treatments become available.
cancers in a state of the art facility."
Dr Adrian Bloor, Consultant Haematologist and Director of Stem Cell Transplantation
Our leukaemia and myeloma service
Consultants treating leukaemia
Acute myeloid leukaemia (AML) and
and myeloma at The Christie Clinic:
myelodysplasia
We are able to treat patients in either an inpatient
Dr Adrian Bloor
or day care environment depending on the level of
Consultant Haematologist
treatment required. We can provide simple treatment such as oral chemotherapy or more complex
Dr Mike Dennis
treatment such as allogeneic stem cell transplants.
Consultant Haematologist
Treatment is determined by diagnosis, and by the stage of disease, under the direction of our
Dr Samar Kulkarni
Consultant Haematologist
Chronic myeloid leukaemia (CML) and
Acute lymphoblastic leukaemia (ALL)
For patients with ALL, chemotherapy may be
Dependent on the stage of disease, we offer a wide
used as a stand-alone treatment or as part of a
range of services. For those patients in early stages
combined treatment with radiotherapy. At The
of these diseases we offer treatments such as oral
Christie Clinic we are able to offer both of these
chemotherapy and targeted therapy. For patients
services through our chemotherapy unit and
who have been diagnosed at a later stage or have
radiotherapy centre, both of which are on site. These
an advanced form of disease, allogeneic
treatments can be given as part of an inpatient
transplants are available.
programme or as day care/outpatient treatment.
Chronic lymphocytic leukaemia (CLL)
At The Christie Clinic we offer a wide range of
Alemtuzumab in combination with methylprednisolone is a
Ofatumumab in advanced stage chronic lymphocytic leukaemia:
At The Christie Clinic we offer treatment to help
treatments for patients with myeloma including
highly effective induction regimen for patients with chronic
results of the UK named patient compassionate use programme.
patients reach a stage of remission. We are able to
chemotherapy, biological therapies, high dose
lymphocytic leukaemia and deletion of TP53: Final results of
Chowdhury O, Varghese A, Pattinson J, Carrington P, Bloor A,
deliver chemotherapy through our inpatient, out
chemotherapy with stem cell support, maintenance
the National Cancer Research Institute CLL206 Trial. Pettitt AR,
Follows GA, Hillmen P, Schuh A. Br J Haematol 2011;155:519
patient and day care facilities. We also provide a
therapy and radiotherapy. The type of treatment
Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford
European development of clofarabine as treatment for older
fully comprehensive stem cell transplant service for
required will be determined by the stage of
JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J,
patients with acute myeloid leukemia considered unsuitable for
patients where necessary. A full range of supportive
illness and other contributing medical factors.
Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin
intensive chemotherapy. Burnett AK, Russell NH, Kell J, Dennis
and complementary treatments are available to
TJ, Rawstron A, Hillmen P. J Clin Oncol 2012;[in press]
M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy
help alleviate symptoms arising from
J, McMullin MF, Hunter A, Das-Gupta E, Clark
the disease and its treatment.
Final results of a multicenter phase 1 study of lenalidomide
R,Carr R, Hills RK. J Clin Oncol. 2010;28:2389
in patients with relapsed or refractory chronic lymphocytic leukemia. Wendtner CM, Hillmen P, Mahadevan D, B Hler A,
United Kingdom National Cancer Research Institute
Uharek L, Coutr S, Frankfurt O, Bloor A, Bosch F, Furman
Haematological Oncology Study Group. The impact of dose
RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD,
escalation and resistance modulation in older patients with acute
Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de
myeloid leukaemia and high risk myelodysplastic syndrome: the
Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-
results of the LRF AML14 trial. Burnett AK, Milligan D, Goldstone
Khan AA. Leuk Lymphoma. 2011;[Epub ahead of print]
A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K. Br J Haematol 2009;145:318
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase
Some early phase II trials in previously untreated multiple
3. Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford
myeloma: The Royal Marsden experience. Sirohi B,
N, Haferlach C, Haferlach T, Gesk S, Score J, Hofmann WK,
Kulkarni S, Powles R. Semin Hematol. 2001;38:209
Hochhaus A, Cross NC, Reiter A. Blood 2011;118:2239
Our lymphoma service
Consultants treating lymphoma
at The Christie Clinic:
The lymphoma service at The Christie Clinic is led and delivered by a team of highly skilled and
Dr Ed Smith
experienced consultants who have national roles
Consultant Clinical Oncologist
advising on lymphoma management. Patients at The Christie Clinic also benefit from access to the
Prof Tim Illidge
regional lymphoma diagnostic service based at
Consultant Clinical Oncologist
The Christie NHS Foundation Trust for accurate diagnosis of lymphomas and associated diseases.
Dr Adrian Bloor
Consultant Haematologist
Planning
Patient care is optimised via a review of all cases
The lymphoma service at The Christie Clinic is
at weekly lymphoma multidisciplinary team (MDT)
led and delivered by a team of highly skilled and
meetings attended by consultant oncologists,
experienced consultants who have national roles
haematologists, radiologists and pathologists.
advising on lymphoma management. Patient
Therapeutic decisions are made after a careful
care is determined through weekly lymphoma
review of all diagnostic material and scans, and
multidisciplinary team (MDT) meetings.
treatment programmes are regularly reviewed and refined by the team to ensure patients receive the
Therapy decisions are discussed by a team of
best possible treatment options.
experienced clinicians after careful review of all diagnostic material and scans. Treatment
programmes are regularly reviewed and refined
The lymphoma team offers comprehensive expertise
to ensure the best possible treatment options.
across all aspects of lymphoma and treatment
The Christie Clinic offers an advanced and
approaches. These include specialist modes such as
comprehensive diagnosis service for accurate
radio-immunotherapy (where we have access to the
diagnosis of lymphomas and associated diseases.
widest experience in the UK), specialist adolescent
Guidelines on the diagnosis and management of Chronic
Reduced dose radiotherapy for local control in non-Hodgkin
care and all forms of stem cell transplantation. In
lymphocytic leukaemia. Oscier D, Fegan C, Hillmen
lymphoma: A randomised phase III trial. Lowry L, Smith P,
The lymphoma service offers comprehensive
addition, The Christie NHS Foundation Trust hosts
P, Illidge T, Johnson S, Matutes E, Milligan D,
Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson
expertise across all aspects of lymphoma and
the supraregional cutaneous lymphoma service,
Pettitt A. Br J Haematol 2012; [in press]
M, Jack A, Hoskin P. Radiother Oncol 2011;100:86
treatment approaches. These include specialist
giving our patients access to total skin electron
approaches such as radio-immunotherapy (where
therapy and extracorporeal photopheresis (ECP).
Brentuximab Vedotin (SGN-35) in Patients with Relapsed or
The future of anti-CD20 monoclonal antibodies: are we making
we have access to the widest experience in the UK),
Refractory Systemic Anaplastic Large Cell Lymphoma: Results of
progress? Alduaij W, Illidge TM. Blood 2011;117:2993
specialist adolescent care, transplantation
a Phase 2 Study. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt
Rapid access clinic
J, Illidge TM, Kennedy D, Shustov A. J Clin Oncol 2012;[in press]
Radioimmunotherapy of lymphoma – a treatment
approaches and a cutaneous lymphoma service
Through our rapid access lump clinic, developed in
Guidelines on the investigation and management of follicular
approach ahead of its time or past its sell by date?
including total skin electron therapy. Through our
collaboration with surgery, radiology and pathology,
lymphoma. McNamara C, Davies J, Dyer M, Hoskin P,
Tim Illidge, J Clin Oncol 2010;28:2944
Lump Clinic we are able to carry out biopsies with
we offer a streamlined service to patients with a
Illidge T, Lyttelton M, Marcus R, Montoto S, Ramsay A,
a rapid results service which allows for prompt
possible lymphoma diagnosis. Our rapid results
Wong W, Ardeshna K. Br J Haematol 2012;156:446
Consensus conference: implementing treatment
classification of lymphoma type. Combined with
recommendations on yttrium-90 immunotherapy in
service, combined with review by the MDT, allows for
Teenage and Young Adults Cancer Survivorship Education
clinical practice - report of a European workshop. Zinzani
review by the MDT, accurate treatment can then
prompt classification of lymphoma type so optimised
Programme: Final Report of a Pilot for the CYP Stream of the
PL, d'Amore F, Bombardieri E, Brammer C, Codina
begin without delay.
treatment can be initiated without delay.
NHS Improvements Cancer Survivorship Initiative. A Hinton
JG, Illidge T, Jurczak W, Linkesch W, Morschhauser F,
and E Smith. National Cancer Survivorship Initiative, NHS
Vandenberghe E, Van Hoof A. Eur J Cancer 2008;44:366
Improvements; Department of Health 2011
Our stem cell transplant service
The transplant team:
maintain exceptional standards of care and education according to internationally set standards.
Dr Adrian Bloor
Consultant Haematologist & Director
Over the last five years The Christie Stem Cell
of Stem Cell Transplantation
Transplant Programme has undertaken 80-120 transplants (autologous and allogeneic) every
Dr Mike Dennis
year, with a sustained increase in activity. In 2009
Consultant Haematologist
it was awarded full JACIE (Joint Accreditation Committee for ISCT and EBMT) accreditation.
Dr Samar Kulkarni
It is also fully licensed by the Human Tissue
Consultant Haematologist
Authority (HTA) and was commended for continued practice at the highest level at the
Ann Davis
last inspection.
Patient care is directly supervised by one of our
Isobel Kearney
highly accomplished consultants and patients have
direct access to the fully trained transplant team through our collaboration with The Christie.
The Christie Clinic offers a comprehensive bone marrow transplant service with all aspects of
care delivered on one site. The Christie Stem Cell
A team of specialist nursing staff (two transplant
Transplant Programme was established in 1982 and
co-ordinators and two apheresis nurses) is
over 1,500 transplants have been performed to date,
responsible for donor identification and stem cell
establishing the programme as one of the UK's
collection. They also act as a point of contact to
major transplant centres and the largest in the
provide information regarding the progress of the
T-cell-depleted reduced-intensity transplantation followed by
Favorable long-term survival after reduced-intensity allogeneic
donor leukocyte infusions to promote graft-versus-lymphoma
transplantation for multiple-relapse aggressive non-Hodgkin's
North West.The Christie Clinic is the first to offer
transplant and details about the admission.
activity results in excellent long-term survival in patients with
lymphoma. Thomson KJ, Morris EC, Bloor A, Cook G,
a private haematology transplant unit within
multiply relapsed follicular lymphoma.Thomson KJ, Morris EC,
Milligan D, Parker A, Clark F, Yung L, Linch DC, Chakraverty
the North West.
In addition to the consultants, we have a team
Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F,
R, Peggs KS, Mackinnon S. J Clin Oncol 2009;27:426
of three nurse clinicians who assist with the care
Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S.
We have invested in the latest infection control
of patients undergoing intensive chemotherapy
J Clin Oncol 2010;28:3695
High response rate to donor lymphocyte infusion after
technologies and our world class consultants
and stem cell transplantation.
allogeneic stem cell transplantation for indolent non-Hodgkin
Impact of in vivo alemtuzumab dose before reduced intensity
lymphoma. Bloor AJ, Thomson K, Chowdhry N, Verfuerth
ensure patients are given the best possible
conditioning and HLA-identical sibling stem cell transplantation:
S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs
treatment options.
Post transplant and late effects
pharmacokinetics, GVHD, and immune reconstitution. Chakraverty
KS, Mackinnon S. Biol Blood Marrow Transplant 2008;:50
We have established links with consultants from
R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan
Transplants are offered for both haematological
other medical specialities to assist with any of the
D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A,
An elective single autograft with high-dose melphalan: single-
malignancies (leukaemia, lymphoma and
complications arising from transplantation. We
Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K,
center study of 451 patients. Sirohi B, Powles R, Mehta J, Rudin
Thomson K, Morris E, Mackinnon S. Blood 2010;116:3080
C, Kulkarni S, Horton C, Saso R, Singhal S, Treleaven
myeloma) and bone marrow failure syndromes
are able to offer extracorporeal photopheresis
J. Bone Marrow Transplant. 2005;36:19
(myelodysplasia and aplastic anaemia). The
(ECP) onsite for the treatment of graft versus
The role of allogeneic SCT in primary myelofibrosis: a British
programme is committed to developing and
host disease (GvHD) in collaboration with the
Society for Blood and Marrow Transplantation study. Stewart
Allogeneic blood and bone-marrow stem-cell transplantation
delivering the highest quality of patient care in
National Blood Service.
WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J,
in haematological malignant diseases: a randomised
stem cell transplantation. We aim to develop and
McQuaker G, Marks DI, Craddock C, McCann S, Russell N,
trial. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar
Cook G, Kottaridis PD; British Society for Blood and Marrow
B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D,
Transplantation. Bone Marrow Transplant 2010;45:1587
Horton C, Long S, Singhal S. Lancet 2000;355:1231
Our diagnostic and laboratory service
Through our partnership with The Christie we have access to a comprehensive haematology and blood transfusion department which is CPA accredited (Clinical Pathology Accreditation) and recognised by the Royal College of Pathology and the Council for Professions Supplementary to Medicine (CPSM). External quality assessments ensure all aspects of the service are delivered comprehensively. The department comprises 14 biomedical scientists and three medical laboratory assistants.
Haematology and blood transfusion
is CPA accredited and is a founder member of the
The haematology and blood transfusion
Cancer Cytogenetics Group (UKCCG).
department provides diagnostic and laboratory services including:
The comprehensive cytogenetics service is provided by a highly skilled team of dedicated scientists and
- Routine investigation laboratory
technologists who offer a timely, efficient and
- Diagnostic immunophenotyping
cost-effective analytical and genetic advisory service
to clinicians to aid the diagnosis and monitoring of
- Blood transfusion
leukaemia. Haemato-lymphoid malignancies are often classified by their genetic abnormalities and
Stem cell laboratory
certain cytogenetic tests are essential for the
The stem cell laboratory, which is based on site,
optimal diagnosis and treatment stratification of
has full JACIE, HTA and MHRA (Medicines
these tumours. Increasingly, cancer drugs are
and Healthcare products Regulatory
being developed that target specific genetic lesions,
Agency) accreditation. The laboratory team
which therefore require a predictive molecular test.
is highly experienced and in 2009/2010
The laboratory is ideally placed to support The
processed and transplanted 210 units of
Christie Clinic's multidisciplinary team meetings and
haematopoietic progenitor cells.
to provide specialised testing for clinical trials.
The comprehensive diagnostic services which
support these functions include immunophenotyping
The haematopathology service is led by Dr Andrew
as well as a wide range of other specialist
Norton, who is the lead consultant pathologist
diagnostic facilities and processes.
for the GMCHMDS, and joint lead for the Primary Cutaneous Lymphoma Supraregional Network. He
is on the national pathology panel for the UKCCG
Oncology cytogenetics at The Christie is a specialist
childhood lymphoma group and the writing
regional service which provides genetic testing to aid
committee for the Royal College of Pathologists'
diagnosis of leukaemia and other tumours, mainly
minimum dataset for lymphoma. Dr Norton
to hospitals in Greater Manchester and the North
has a national and international reputation
West of England. Handling approximately 5,000
with over 20 years' experience as a consultant
referrals per year, it is one of the largest
in haematopathology. He has served as a
specialist cancer genetics units in the UK.
pathology representative to the UK Lymphoma
The department is the nominated service for
Group, expert pathologist to the British National
leukaemia cytogenetic testing for two local
Lymphoma Investigation and Imperial
cancer networks and for the Greater Manchester
Cancer Research Fund, as well as on a variety of
and Cheshire Haematological Malignancy
national and international studies/working parties.
Diagnostic Service (GMCHMDS). The department
complementary care
Making a referral
The Christie Clinic provides all patients with access
If you would like to refer a patient to one of our consultants please
to the complementary therapists who visit The Clinic
contact us through our referral helpline or fax a referral letter.
weekly. They provide a range of holistic therapies including massage and reflexology.
If you have a general enquiry about our haematology unit at The Christie Clinic please do not hesitate to contact us at
We have a dedicated dietician and physiotherapist available to patients onsite as and when required.
The Christie Clinic, Wilmslow Road
Both the dietician and the physiotherapist take part
Manchester, M20 4BX.
in the active management of our patients and help in achieving a speedy and organised discharge.
Helpline: 0161 918 7296
Fax: 0161 446 8027
All patients and their families have access to a
psychology counsellor if required and this service
can be accessed through a member of the nursing team or the consultant leading their care.
The first six sessions are free of charge and can be used at any time during the patient's illness. If further sessions are needed we are happy to liaise with insurers as required.
Source: http://www.thechristieclinic.co.uk/wp-content/uploads/2014/05/Haematology-brochure-V8.pdf
Hindawi Publishing CorporationBioMed Research InternationalVolume 2013, Article ID 540465, 13 pageshttp://dx.doi.org/10.1155/2013/540465 Research ArticleCharacterization and Dynamic Behavior of Wild Yeast duringSpontaneous Wine Fermentation in Steel Tanks and Amphorae Cecilia Díaz,1 Ana María Molina,2 Jörg Nähring,1 and Rainer Fischer1
HOT SOURCE EXPERT INSIGHTS INTO SAFE, SUSTAINABLE AND HIGH-QUALITY FOOD ISSUE 3 • NOVEMBER • 2013 UPCOMING CHANGES TO ISO 9001 AND ISO 14001 UNANNOUNCED AUDITS: A GUIDE TO THE NEW BRC REQUIREMENTSISOTOPE TESTING BREAKS NEW GROUND IN FOOD TECHNOLOGYGMO FOODS AND LABELING DEAR READER, Complying with quality, safety and sustainability requirements is an ongoing responsibility. To help you meet the challenge, this issue of Hot Source looks at forthcoming revisions to ISO 9001 and ISO 14001 and reminds us of the planned timetable. Many private label suppliers will also be affected by a major retailer's announcement that all suppliers must undergo BRC unannounced audits. We explain what you can expect and what will be expected of your team.